These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36564063)

  • 1. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
    Lv ZY; Mo QP; Tang HC; Zheng SS
    Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
    Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
    Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Vennin C; Spruyt N; Robin YM; Chassat T; Le Bourhis X; Adriaenssens E
    Cancer Lett; 2017 Jan; 385():198-206. PubMed ID: 27780718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.
    Liu X; Miao W; Huang M; Li L; Dai X; Wang Y
    Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis.
    Ren L; Zhou H; Lei L; Zhang Y; Cai H; Wang X
    Bioengineered; 2021 Dec; 12(1):5266-5278. PubMed ID: 34424807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
    Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
    J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.
    Peng WX; Huang JG; Yang L; Gong AH; Mo YY
    Mol Cancer; 2017 Oct; 16(1):161. PubMed ID: 29041978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
    Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
    PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer.
    Li Y; Jiang B; Zhu H; Qu X; Zhao L; Tan Y; Jiang Y; Liao M; Wu X
    Tumour Biol; 2017 Jun; 39(6):1010428317705790. PubMed ID: 28635401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.